MRSN Insider Trading

Insider Ownership Percentage: 11.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $154,116.74

Mersana Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Mersana Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Mersana Therapeutics Share Price & Price History

Current Price: $0.31
Price Change: Price Increase of +0.0495 (18.94%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for MRSN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$0.31Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Mersana Therapeutics (NASDAQ:MRSN)

93.92% of Mersana Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MRSN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$3.48Mbought$1.12MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal InflowsTotal Outflows
Mersana Therapeutics logo
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Read More on Mersana Therapeutics

Today's Range

Now: $0.31
Low: $0.26
High: $0.31

50 Day Range

MA: $0.48
Low: $0.26
High: $0.75

52 Week Range

Now: $0.31
Low: $0.26
High: $3.96

Volume

2,617,237 shs

Average Volume

2,464,908 shs

Market Capitalization

$38.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Who are the company insiders with the largest holdings of Mersana Therapeutics?

Mersana Therapeutics' top insider investors include:
  1. Timothy B Lowinger (SVP)
  2. Anna Protopapas (Director)
  3. Martin H Jr Huber (CEO)
  4. Brian Deschuytner (CFO)
  5. Alejandra Carvajal (SVP)
  6. Ashish Mandelia (CAO)
  7. Mohan Bala (SVP)
  8. Tushar Misra (SVP)
Learn More about top insider investors at Mersana Therapeutics.